ZA200607134B - Inhibitors of hepatitis C virus NS3 protease - Google Patents

Inhibitors of hepatitis C virus NS3 protease

Info

Publication number
ZA200607134B
ZA200607134B ZA200607134A ZA200607134A ZA200607134B ZA 200607134 B ZA200607134 B ZA 200607134B ZA 200607134 A ZA200607134 A ZA 200607134A ZA 200607134 A ZA200607134 A ZA 200607134A ZA 200607134 B ZA200607134 B ZA 200607134B
Authority
ZA
South Africa
Prior art keywords
hepatitis
protease
virus
inhibitors
Prior art date
Application number
ZA200607134A
Other languages
English (en)
Inventor
Stephane L Bogen
Ruan Sumei
Arasappan Ashok
Latha G Nair
Bennett Frank
Njoroge F George
Pan Weidong
Kevin X Chen
Venkatraman Srikanth
Sannigrahi Mousumi
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200607134B publication Critical patent/ZA200607134B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200607134A 2004-02-27 2006-08-25 Inhibitors of hepatitis C virus NS3 protease ZA200607134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54825104P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ZA200607134B true ZA200607134B (en) 2008-04-30

Family

ID=34919341

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607134A ZA200607134B (en) 2004-02-27 2006-08-25 Inhibitors of hepatitis C virus NS3 protease

Country Status (12)

Country Link
US (2) US7205330B2 (fr)
EP (1) EP1730165A1 (fr)
JP (1) JP4745327B2 (fr)
KR (1) KR20060124725A (fr)
CN (1) CN1950393A (fr)
AR (1) AR047901A1 (fr)
AU (1) AU2005219859A1 (fr)
CA (1) CA2557322A1 (fr)
IL (1) IL177503A0 (fr)
TW (1) TW200536528A (fr)
WO (1) WO2005085275A1 (fr)
ZA (1) ZA200607134B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901602T2 (xx) 1996-10-18 1999-10-21 Vertex Pharmaceuticals Incorporated Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006117567A2 (fr) * 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Modulation d'enzyme et de recepteur
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
AR055198A1 (es) * 2005-06-02 2007-08-08 Schering Corp Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130687A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Taux de concentration foie/plasma pour le dosage de l'inhibiteur de protease du virus de l'hepatite c
EP1891089B1 (fr) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de protease du VHC en combinaison avec des aliments
WO2006130554A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
NZ563369A (en) * 2005-06-02 2011-03-31 Schering Corp Controlled-release formulation useful for treating disorders associated with hepatitus C virus
WO2006130552A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1999129B1 (fr) 2005-10-11 2010-12-29 Intermune, Inc. Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
AR056805A1 (es) 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007120595A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
MX2009006056A (es) * 2006-12-07 2009-06-16 Schering Corp Formulacion de matriz sensible al ph.
WO2008086053A1 (fr) * 2007-01-03 2008-07-17 Virobay, Inc. Inhibiteurs du vhc
EP2119702A4 (fr) 2007-01-31 2010-12-08 Dainippon Sumitomo Pharma Co Dérivé d'amide
SG174809A1 (en) * 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
AR066528A1 (es) * 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
WO2009047264A1 (fr) * 2007-10-10 2009-04-16 Novartis Ag Composés organiques et leurs utilisations
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
CA2720729A1 (fr) 2008-04-15 2009-11-26 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CA2763140A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composes antiviraux de trois fractions d'aryle liees pour traiter des maladies telles que l'hepatite c
WO2011066241A1 (fr) 2009-11-25 2011-06-03 Schering Corporation Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales
CA2785488A1 (fr) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Composes tricycliques fusionnes et leurs methodes d'utilisation pour le traitement de maladies virales
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2012018534A2 (fr) 2010-07-26 2012-02-09 Schering Corporation Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
CA2812779A1 (fr) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Derives tetracycliques condenses et procedes d'utilisation de ceux-ci dans le traitement de maladies virales
US9061041B2 (en) 2011-04-13 2015-06-23 Merck Sharp & Dohme Corp. 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033900A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033899A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
WO2013039876A1 (fr) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI532485B (zh) 2011-10-21 2016-05-11 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）的方法
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2016129983A1 (fr) * 2015-02-13 2016-08-18 Latvian Institute Of Organic Synthesis Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co. Ltd., Tokio/Tokyo Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
CA2079105C (fr) 1990-04-04 2000-06-13 Michael Houghton Protease du virus de l'hepatite c
JPH07109257A (ja) * 1993-08-20 1995-04-25 Banyu Pharmaceut Co Ltd エラスターゼ阻害物質
EP0639585A1 (fr) 1993-08-20 1995-02-22 Banyu Pharmaceutical Co., Ltd. Inhibiteur d'élastase
US5884323A (en) * 1995-10-13 1999-03-16 3Com Corporation Extendible method and apparatus for synchronizing files on two different computer systems
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
TR199901602T2 (xx) 1996-10-18 1999-10-21 Vertex Pharmaceuticals Incorporated Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6143715A (en) 1997-08-11 2000-11-07 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CA2405043A1 (fr) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
RU2002131163A (ru) 2000-04-19 2004-06-27 Шеринг Корпорейшн (US) Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AU8063701A (en) 2000-07-21 2002-02-05 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
MY143322A (en) 2000-07-21 2011-04-15 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6911428B2 (en) 2000-12-12 2005-06-28 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1408031A1 (fr) 2002-10-09 2004-04-14 3 D Gene Pharma Derivés de pyrolidine comme médicaments contre Hepatitis C

Also Published As

Publication number Publication date
EP1730165A1 (fr) 2006-12-13
JP4745327B2 (ja) 2011-08-10
US20070142301A1 (en) 2007-06-21
AU2005219859A1 (en) 2005-09-15
JP2007535496A (ja) 2007-12-06
CA2557322A1 (fr) 2005-09-15
KR20060124725A (ko) 2006-12-05
IL177503A0 (en) 2006-12-10
US7423058B2 (en) 2008-09-09
TW200536528A (en) 2005-11-16
US20050267043A1 (en) 2005-12-01
CN1950393A (zh) 2007-04-18
AR047901A1 (es) 2006-03-01
WO2005085275A1 (fr) 2005-09-15
US7205330B2 (en) 2007-04-17

Similar Documents

Publication Publication Date Title
IL177503A0 (en) Inhibitors of hepatitis c virus ns3 protease
IL177545A0 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
HK1099028A1 (en) Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
HK1118066A1 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ZA200607096B (en) Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
IL240244A0 (en) Macrocyclic inhibitors of hepatitis c virus
TWI367211B (en) Hcv ns-3 serine protease inhibitors
AP2585A (en) Macrocyclic inhibitors of hepatitis C virus
AP2473A (en) Macrocyclic inhibitors of hepatitis C virus
DE602006009280D1 (de) Inhibitoren der hcv-ns3-protease
HK1095820A1 (en) 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
ME01318B (fr) Inhibiteurs macrocycliques du virus de l'hépatite c
HK1116503A1 (en) Macrocyclic inhibitors of hepatitis c virus
AU2009225346B2 (en) Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease